全文获取类型
收费全文 | 21944篇 |
免费 | 1632篇 |
国内免费 | 517篇 |
专业分类
耳鼻咽喉 | 78篇 |
儿科学 | 720篇 |
妇产科学 | 236篇 |
基础医学 | 935篇 |
口腔科学 | 67篇 |
临床医学 | 4874篇 |
内科学 | 4701篇 |
皮肤病学 | 146篇 |
神经病学 | 1298篇 |
特种医学 | 1293篇 |
外国民族医学 | 1篇 |
外科学 | 3681篇 |
综合类 | 2852篇 |
现状与发展 | 4篇 |
预防医学 | 705篇 |
眼科学 | 141篇 |
药学 | 1323篇 |
19篇 | |
中国医学 | 470篇 |
肿瘤学 | 549篇 |
出版年
2024年 | 196篇 |
2023年 | 371篇 |
2022年 | 689篇 |
2021年 | 875篇 |
2020年 | 932篇 |
2019年 | 849篇 |
2018年 | 783篇 |
2017年 | 822篇 |
2016年 | 796篇 |
2015年 | 806篇 |
2014年 | 1509篇 |
2013年 | 1604篇 |
2012年 | 1273篇 |
2011年 | 1342篇 |
2010年 | 1100篇 |
2009年 | 1057篇 |
2008年 | 1033篇 |
2007年 | 971篇 |
2006年 | 905篇 |
2005年 | 818篇 |
2004年 | 623篇 |
2003年 | 602篇 |
2002年 | 484篇 |
2001年 | 422篇 |
2000年 | 340篇 |
1999年 | 263篇 |
1998年 | 276篇 |
1997年 | 277篇 |
1996年 | 219篇 |
1995年 | 231篇 |
1994年 | 185篇 |
1993年 | 153篇 |
1992年 | 159篇 |
1991年 | 122篇 |
1990年 | 115篇 |
1989年 | 108篇 |
1988年 | 107篇 |
1987年 | 67篇 |
1986年 | 85篇 |
1985年 | 106篇 |
1984年 | 88篇 |
1983年 | 48篇 |
1982年 | 62篇 |
1981年 | 52篇 |
1980年 | 39篇 |
1979年 | 35篇 |
1978年 | 21篇 |
1977年 | 22篇 |
1976年 | 19篇 |
1975年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 19 毫秒
951.
Roza Chaireti Rupesh Rajani Annika Bergquist Tor Melin Inga-Lill Friis-Liby Marjo Kapraali Stergios Kechagias Tomas L. Lindahl Sven Almer 《Thrombosis research》2014
Introduction
In recent years there have been increasing evidence associating liver disease with hypercoagulability, rather than bleeding. The aim of the study was to evaluate the haemostatic potential in patients with liver disease.Patients and methods
We measured thrombin generation in the presence and absence of thrombomodulin in patients with portal vein thrombosis (PVT, n = 47), Budd-Chiari syndrome (BCS, n = 15) and cirrhosis (n = 24) and compared the results to those obtained from healthy controls (n = 21). Fifteen patients with PVT and 10 patients with BCS were treated with warfarin and were compared to an equal number of patients with atrial fibrillation matched for prothrombin time-international normalized ratio. We assessed resistance to thrombomodulin by using ratios [marker measured in the presence/absence of thrombomodulin].Results
There were no differences in thrombin generation between patients on warfarin treatment and their controls. Cirrhotic patients generated more thrombin in the presence of thrombomodulin and exhibited thrombomodulin resistance compared to controls [p = 0.006 for endogenous thrombin potential (ETP) and p < 0.001 for peak thrombin and both ratios ETP and peak] and patients with non-cirrhotic PVT (p = 0.001, p = 0.006, p < 0.001, p < 0.001 for ETP, peak, ratio ETP, ratio peak, respectively). The patients with cirrhotic PVT exhibited higher ETP (p = 0.044) and peak (p = 0.02) in the presence of thrombomodulin than controls, as well as thrombomodulin resistance (ETP and peak ratios: p = 0.001).Conclusions
Hypercoagulability and thrombomodulin resistance in patients with cirrhosis were independent of the presence of splanchnic vein thrombosis. The hypercoagulability in patients with cirrhotic PVT could have implications for considering longer or more intensive treatment with anticoagulants in this group. 相似文献952.
Elizabeth S. Mearns Christine G. Kohn Ju-Sung Song Jessica Hawthorne Joy Meng C. Michael White Monika K. Raut Jeff R. Schein Craig I. Coleman 《Thrombosis research》2014
Introduction
Patients with venous thromboembolism (VTE) frequently require vitamin K antagonists (VKAs) to prevent recurrent events, but their use increases hemorrhage risk. We performed a meta-analysis to assess the quality of international normalized ratio (INR) control, identify study-level predictors of poor control and to examine the relationship between INR control and adverse outcomes in VTE patients.Materials and Methods
We searched bibliographic databases (1990-June 2013) for studies of VTE patients receiving adjusted-dose VKAs that reported time in range (2.0-3.0) or proportion of INRs in range and/or reported INR measurements coinciding with thromboembolic or hemorrhagic events. Meta-analysis and meta-regression analysis was performed.Results
Upon meta-analysis, studies found 59% (95%CI: 54-64%) of INRs measured and 61% (95%CI: 59-63%) of the time patients were treated were spent outside the target range of 2.0-3.0; with a tendency for under- versus over-anticoagulation. Moreover, this poor INR control resulted in a greater chance of recurrent VTE (beta-coefficient = -0.46, p = 0.01) and major bleeding (beta-coefficient = -0.30, p = 0.02). Patients with an INR < 2.0 made up 58% (95%CI: 39-77%) of VTE cases, while those with an INR > 3.0 made up 48% (95%CI: 34-61%) of major hemorrhage cases. Upon meta-regression, being VKA-naïve (-14%, p = 0.04) and treated in the community (-7%, p < 0.001) were associated with less time in range, while being treated in Europe/United Kingdom (compared to North America) was associated with (11%, p = 0.003) greater time.Conclusions
Strategies to improve INR control or alternative anticoagulants, including the newer oral agents, should be widely implemented in VTE patients to reduce the rate of recurrent events and bleeding. 相似文献953.
954.
M. Martin 《Journal of molecular medicine (Berlin, Germany)》1993,71(6):471-477
Summary The PHLECO Study (phlebothrombosis conservative therapy) is a multicenter investigation of patients with deep vein thrombosis receiving conservative nonfibrinolytic hospital treatment. A second study (part II : PHLEFI, phlebothrombosis fibrinolytic treatment) to be published later deals with the outcome of fbrnolytic therapy. In both studies the incidence of life-threatening sequelae, such as pulmonary embolism, is of major interest. The 49 medical departments participating in the study mailed the relevant data to the Duisburg Coordination Center for further data analysis and the following information was gained: (a) In descending order of frequency, the clinical conditions of thrombosis were: immobility, postoperative status, malignancy, hormone treatment, posttraumatic conditions, and pregnancy. (b) In descending order of frequency, the sites of thrombosis were: femoral vein, calf vein, iliac vein, popliteal vein, and subclavian vein. Left-sided thrombosis predominated in the iliac and subclavian vein groups. (c) In descending order of frequency, the treatment regimens employed were: intravenous heparin+ oral anticoagulants, intravenous heparin+subcutaneous heparin, intravenous heparin alone, subcutaneous heparin alone, intravenous heparin+subcutaneous heparin+oral anticoagulants, subcutaneous heparin+oral anticoagulants, intravenous heparin + platelet aggregation inhibitors. (d) The average hospital stay was 23.7 + 15.6 days. No correlation existed between duration of hospital stay and particular types of therapy. (e) The incidence of nonfatal pulmonary embolism was 16.1% while that of fatal pulmonary embolism was 2.33%. (f) Women outnumbered men in the group with fatal pulmonary embolism, and the death rate among older patients was higher than that among younger patients. (g) Patients with fatal pulmonary embolism had a shorter history of thrombosis than patients in the unselected cohort (patients with and without pulmonary embolism). (h) Iliac vein thrombosis correlated with the highest incidence of fatal pulmonary embolism, with the right iliac vein predominating. (i) Calf vein thrombosis produced pulmonary embolism only very rarely, and pulmonary embolism was not observed in the group of patients with subclavian vein thrombosis.Abbreviations PHLECO
phlebothrombosis conservative treatment
- PHLEFI
phlebothrombosis fibrinolytic treatment
- DVT
deep vein thrombosis
PHLECO Coordination CenterThis study was supported by a grant from the Verein zur Förderung der Gesundheit im Alter e.V.The study center and the names of participating clinicians are listed at the end of this paper 相似文献
955.
Asher Bashiri Tal Lazer Eliezer Burstein Ana Smolin Simcha Lazer Zvi H. Perry 《The journal of maternal-fetal & neonatal medicine》2013,26(3):241-247
Objective. To assess the clinical characteristics of maternal and neonatal outcome among women with cerebrovascular accidents (CVA) during pregnancy.Methods. Our computerized database was used to identify patients with CVA during pregnancy and puerperium from January 1988 to March 2004. Their medical records were identified and reviewed.Results. There were 16 cases of CVA among 173 803 deliveries, giving a risk of almost one case per 10 000 pregnant women. Out of 16 patients, 14 (88%) had a stroke and the remaining two cases were diagnosed with venous thrombosis. Of those 14 cases, nine (64%) had ischemic strokes and five (36%) had hemorrhagic strokes. Ten of the CVAs occurred antepartum, two intrapartum and four postpartum. Hypertensive disorders were diagnosed in 75% (12/16) of the patients. Out of these 12 patients with hypertension, 9 (75%) suffered from preeclampsia. One woman had a history of chronic hypertension. Smoking was associated with 63% (10/16) of the cases. There were two maternal deaths, both in women who had hemorrhagic strokes, and both in the first half of the study (1994 and 1996). Nine out of 16 women (56%), were delivered within 48 hours of the CVA including 7 (78%) antepartum, and two (22%) intrapartum. Cesarean deliveries were performed in 11/16 women (69%) including 8/10 with CVAs occurring antepartum, 1/2 intrapartum and 2/4 postpartum. One case of neonatal mortality was identified in a patient who was delivered at 24 gestational weeks.Conclusions. (1) Hypertensive disorders and smoking were the most important factors associated with CVA during pregnancy. (2) Maternal mortality was high among patients with CVA during pregnancy. (3) Neonatal outcome was considered generally good in cases of CVA. 相似文献
956.
957.
958.
《Burns : journal of the International Society for Burn Injuries》2019,45(4):818-824
IntroductionPatients recovering from burn injury are at high risk of developing deep venous thrombosis (DVT). While 30-mg twice-daily enoxaparin is accepted as the standard prophylactic dose, recent evidence in injured patients suggests this dosing strategy may result in sub-optimal pharmacologic DVT prophylaxis. We hypothesized that standard enoxaparin dosing would result in inadequate DVT prophylaxis in burn patients.MethodsA retrospective review of an ABA-verified Burn center’s registry from January 2012 — December 2016 identified patients with peak plasma anti-Xa levels to monitor the efficacy of pharmacologic DVT prophylaxis. Patients ≥18 years old were included if they received at least 3 doses of enoxaparin and had appropriately timed peak anti-Xa levels. We analyzed data including patient demographics, body weight, body mass index (BMI) and total body surface area burn (TBSA). Diagnosis of DVT was collected.ResultsDuring the study period, 393 patients were screened with a plasma anti-Xa levels. Of the 157 patients that met inclusion criteria, 81 (51.6%) achieved target peak plasma anti-Xa levels (0.2–0.4 IU/mL) on standard 30-mg twice-daily prophylactic enoxaparin and 76 (48.4%) had sub-prophylactic levels. Sub-prophylactic patients were more likely to be male, have increased body weight and elevated BMI. 49 of the 76 sub-prophylactic patients received a dose-adjustment in order to reach target anti-Xa levels; 37 patients required 40 mg twice-daily, 10 required 50 mg twice-daily and 2 required 60 mg twice-daily. The overall DVT rate was 3.8%.ConclusionsThe current recommended prophylactic dose of 30-mg twice-daily enoxaparin is inadequate in many burn patients. Alternate dosing strategies should be considered to increase the number of burn patients achieving target prophylactic anti-Xa levels. Determining whether prophylactic enoxaparin dose adjustment decreases DVT rates in burn injured patients should be evaluated in future prospective trials. 相似文献
959.
960.